Association of Glutamine and Glutamate Metabolism with Mortality among Patients at Nutritional Risk-A Secondary Analysis of the Randomized Clinical Trial EFFORT - Wunderle, C.; von Arx, D.; Mueller, S. C.; Bernasconi, L.; Neyer, P.; Tribolet, P.; Stanga, Z.; Mueller, B.; Schuetz, P. (Nutrients, 2024)
Glutamine and its metabolite glutamate serve as the main energy substrates for immune cells, and their plasma levels drop during severe illness. Therefore, glutamine supplementation in the critical care setting has been advocated. However, little is known about glutamine metabolism in severely but not critically ill medical patients. We investigated the prognostic impact of glutamine metabolism in a secondary analysis of the Effect of Early Nutritional Support on Frailty, Functional Outcomes, and Recovery of Malnourished Medical Inpatients Trial (EFFORT), a randomized controlled trial comparing individualized nutritional support to usual care in patients at nutritional risk. Among 234 patients with available measurements, low plasma levels of glutamate were independently associated with 30-day mortality (adjusted HR 2.35 [95% CI 1.18-4.67, p = 0.015]). The impact on mortality remained consistent long-term for up to 5 years. No significant association was found for circulating glutamine levels and short- or long-term mortality. There was no association of glutamate nor glutamine with malnutrition parameters or with the effectiveness of nutritional support. This secondary analysis found glutamate to be independently prognostic among medical inpatients at nutritional risk but poorly associated with the effectiveness of nutritional support. In contrast to ICU studies, we found no association between glutamine and clinical outcome.
Keywords: journalArticle; *Frailty; *Malnutrition; Critical Care; Glutamic Acid; Glutamine; Humans; Inpatients; Science, and Abbott Nutrition. The institution of Z.S. received research support; biomarker; from Nestle Health Science, Abbott Nutrition, Fresenius Kabi, and B. Braun. All; glutamate; individualized nutrition support; malnutrition; other authors declare no conflicts of interest; polymorbid patient; unrelated to this project from Roche, Thermo Fisher, bioMerieux, Nestle Health